Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15775835 | 0.93 | ALDH1A1 (0.46) | ALDH1A1DRD2GFERGAATDP1 | |
| SCHEMBL15775419 | 0.88 | ALDH1A1 (0.43) | ALDH1A1DRD2GFERGAATDP1 | |
| SCHEMBL17396731 | 0.83 | MGAM (0.41) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL23766181 | 0.81 | ALDH1A1 (0.51) | ALDH1A1DRD2GFERTDP1HTT | |
| SCHEMBL17273760 | 0.79 | HDAC3 (0.51) | DRD2 | |
| SCHEMBL30803496 | 0.79 | ALDH1A1 (0.48) | ALDH1A1DRD2GFERTDP1BRD4 | |
| SCHEMBL21670036 | 0.79 | MGAM (0.41) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL20130790 | 0.79 | ALDH1A1 (0.42) | ALDH1A1DRD2GFERGAATDP1 | |
| SCHEMBL18605891 | 0.79 | ALDH1A1 (0.49) | ALDH1A1DRD2GFERGAATDP1 | |
| SCHEMBL28017558 | 0.79 | ALDH1A1 (0.42) | ALDH1A1DRD2GFERGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3865152-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2021-08-18 | — | — | EP | disclosed |
| EP-2925765-B1 | SUBSTITUTED TRIAZOLE BORONIC ACID COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-12-14 | — | — | EP | disclosed |
| US-9464098-B2 | Substituted triazole boronic acid compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150329565-A1 | SUBSTITUTED TRIAZOLE BORONIC ACID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-19 | — | — | US | disclosed |
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | disclosed |
| EP-2925765-A1 | SUBSTITUTED TRIAZOLE BORONIC ACID COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2925746-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014086664-A1 | SUBSTITUTED TRIAZOLE BORONIC ACID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086663-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086663-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329565-A1 | SUBSTITUTED TRIAZOLE BORONIC ACID COMPOUNDS | HDAC7, PSMB7, MALT1 | ALDH1A1 1657/4885DRD2 4363/4885GFER 4161/4885 |
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | HDAC7, PSMB7, IKZF3 | ALDH1A1 1540/4885DRD2 4508/4885GFER 4667/4885 |
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | ALDH1A1 2585/4885DRD2 4439/4885GFER 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.